Navigation Links
TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
Date:12/5/2011

MALVERN, Pa., Dec. 5, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead Smac mimetic drug candidate, TL32711, in elderly patients with acute myelogenous leukemia (AML). The investigator-initiated study is being conducted at the Hospital of the University of Pennsylvania and is an open-label, non-randomized trial that will evaluate the safety, tolerability and clinical response activity of TL32711 in patients aged 60 years or greater who have relapsed or primary refractory AML.

"In preclinical studies on primary human AML samples, TL32711 inhibits the growth and survival of AML cells as demonstrated in colony forming assays and a xenotransplantation model of the disease," said Martin Carroll, M.D., of the Hospital of the University of Pennsylvania. "These encouraging data along with TL32711's novel mechanism of action support its clinical development for AML where new treatment options are needed especially for the elderly."

"This clinical study represents another important step in advancing TL32711 as a potential treatment for AML and supports our goal of providing improved therapies for patients with cancer," said John Gill, TetraLogic's President and Chief Executive Officer.  "The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins (IAPs) represents a new broadly applicable approach to treat cancers that are normally resistant to therapies, including AML."

About TL32711
TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological mali
'/>"/>

SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
(Date:8/28/2014)...   SunTrust Robinson Humphrey (STRH) today ... its equity research team in biotechnology and oilfield ... equity research demonstrates our commitment to providing our ... their investment decision making," said Biff Woodruff ... to make significant investments in differentiated content at ...
(Date:8/28/2014)... Scientists, researchers, and technologists will converge in ... 2014 symposium. Marking its 46th year, the annual ... 14-17 September. The event is sponsored by SPIE, ... The premier conference for basic and applied issues which ... will engage researchers and engineers from numerous industries and ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... , HOUSTON, Nov. 12 An experiment by college students ... to orbit aboard space shuttle Atlantis. , (Logo: ... at Texas Southern University in Houston developed the experiment that ... is scheduled to launch at 2:28 p.m. EST on Nov. ...
... Reportlinker.com announces that a new market research ... Diclofenac sodium (CAS 15307-79-6) Market ... http://www.reportlinker.com/p0163683/Diclofenac-sodium-(CAS-15307-79-6)-Market-Research-Report-2009.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... (CAS 15307-79-6) Market Research Report 2009, presents ...
... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that ... with part of the proceeds from the $300 million securitization ... of PDL on December 1, 2009 will be paid a ... significant amount of convertible securities outstanding, the amount of the ...
Cached Biology Technology:Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Reportlinker Adds Diclofenac sodium (CAS 15307-79-6) Market Research Report 2009 2PDL BioPharma Announces Special Dividend Payment 2
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
(Date:8/29/2014)... modern materials that are light, flexible and highly conductive ... electronic paper. , Making such concepts affordable enough for ... of working with copper nanowires and a PVA "nano ... in the field of ultra-lightweight "aerogel monoliths" has largely ... nanowires. , By turning instead to copper, both ...
(Date:8/28/2014)... marine protected areas is needed to protect fish species ... from the Wildlife Conservation Society and other organizations, previous ... largest numbers of species, often at the expense of ... , Many vital ecological functions of ocean ... food for millions of people. This study uncovers ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... consumers like a crisp bite. Apple breeders know that ... in apples. Because new apple varieties must be tested ... are constantly searching for methods to accurately measure traits ... wayusing panels of experts who taste-test each fruit. This ...
... a species of the plant pathogen Rhizoctonia ... cultivars during nursery production, particularly in the southern ... the pathogen, spreading the devastating, costly disease through ... submerging terminal leafy cuttings of ,Gumpo White, azalea ...
... from North Carolina State University, Sandia National Laboratories, and ... technology that uses microneedles to allow doctors to detect ... continuously do so for an extended period of time. ... electrochemical sensors that can be used to detect specific ...
Cached Biology News:Computerized tool takes a bite out of traditional apple testing 2Thermotherapy rids azaleas of deadly fungal disease 2Microneedle sensors may allow real-time monitoring of body chemistry 2